As a young researcher just completing his MD and PhD at Johns Hopkins University in 1988, Dr. David Carbone was looking for ways to apply the latest tools in molecular biology. He wanted to make an impact. After attending a talk about cancer mutations, Dr. Carbone realized that lung cancer was inadequately treated and lung cancer patients could really benefit from genetic and molecular therapeutics. Since then, Dr. Carbone has been striving to improve lung cancer detection and treatment.
The results of his work have been far-reaching. From discovering factors that cause cancer-associated immunosuppression to developing serum protein biomarker tests, Dr. Carbone has made a tremendous impact on lung cancer. Armed with intense scientific curiosity and dogged determination, Dr. Carbone has published more than 150 peer-reviewed publications and review articles. He is often invited to serve on NCI grant review panels and his laboratory has earned continuous NCI funding since early in his career.